Sharon M Moe1,2, Leah Wetherill3, Brian Scott Decker4, Dongbing Lai3, Safa Abdalla5, Jin Long5, Matteo Vatta3, Tatiana M Foroud3, Glenn M Chertow5. 1. Division of Nephrology, Department of Medicine and smoe@iu.edu. 2. Department of Medicine, Roudebush Veterans Administration Medical Center, Indianapolis, Indiana; and. 3. Department of Medical and Molecular Genetics, Indiana University School of Medicine, Indianapolis, Indiana. 4. Division of Nephrology, Department of Medicine and. 5. Division of Nephrology, Department of Medicine, Stanford School of Medicine, Stanford, California.
Abstract
BACKGROUND AND OBJECTIVES: We tested the hypothesis that single nucleotide polymorphisms (SNPs) in the calcium-sensing receptor (CASR) alter the response to the calcimimetic cinacalcet. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: We analyzed DNA samples in the Evaluation of Cinacalcet HCl Therapy to Lower Cardiovascular Events (EVOLVE) trial, a randomized trial comparing cinacalcet to placebo on a background of usual care. Of the 3883 patients randomized, 1919 (49%) consented to DNA collection, and samples from 1852 participants were genotyped for 18 CASR polymorphisms. The European ancestry (EA; n=1067) and African ancestry (AfAn; n=405) groups were assessed separately. SNPs in CASR were tested for their association with biochemical measures of mineral metabolism at baseline, percent change from baseline to 20 weeks, and risk of clinical fracture as dependent variables. RESULTS: There were modest associations of CASR SNPs with increased baseline serum parathyroid hormone and bone alkaline phosphatase primarily with the minor allele in the EA group (all P≤0.03), but not in the AfAn sample. In contrast, there was a modest association of decreased baseline serum calcium and FGF23 with CASR SNPs (P=0.04) primarily with the minor allele in the AfAn but not in the EA sample. The minor allele of two SNPs was associated with decreased percent reduction in parathyroid hormone from baseline to 20 weeks in the EA population (P<0.04) and this was not altered with cinacalcet. In both EA and AfAn, the same SNP (rs9740) was associated with decreased calcium with cinacalcet treatment (EA and AfAn P≤0.03). Three SNPs in high linkage disequilibrium were associated with a higher risk of clinical fracture that was attenuated by cinacalcet treatment in the EA sample (P<0.04). CONCLUSIONS: These modest associations, if validated, may provide explanations for differences in CKD-mineral bone disorder observed in EA and AfAn populations, and for differential biochemical responses to calcimimetics.
RCT Entities:
BACKGROUND AND OBJECTIVES: We tested the hypothesis that single nucleotide polymorphisms (SNPs) in the calcium-sensing receptor (CASR) alter the response to the calcimimetic cinacalcet. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: We analyzed DNA samples in the Evaluation of Cinacalcet HCl Therapy to Lower Cardiovascular Events (EVOLVE) trial, a randomized trial comparing cinacalcet to placebo on a background of usual care. Of the 3883 patients randomized, 1919 (49%) consented to DNA collection, and samples from 1852 participants were genotyped for 18 CASR polymorphisms. The European ancestry (EA; n=1067) and African ancestry (AfAn; n=405) groups were assessed separately. SNPs in CASR were tested for their association with biochemical measures of mineral metabolism at baseline, percent change from baseline to 20 weeks, and risk of clinical fracture as dependent variables. RESULTS: There were modest associations of CASR SNPs with increased baseline serum parathyroid hormone and bone alkaline phosphatase primarily with the minor allele in the EA group (all P≤0.03), but not in the AfAn sample. In contrast, there was a modest association of decreased baseline serum calcium and FGF23 with CASR SNPs (P=0.04) primarily with the minor allele in the AfAn but not in the EA sample. The minor allele of two SNPs was associated with decreased percent reduction in parathyroid hormone from baseline to 20 weeks in the EA population (P<0.04) and this was not altered with cinacalcet. In both EA and AfAn, the same SNP (rs9740) was associated with decreased calcium with cinacalcet treatment (EA and AfAn P≤0.03). Three SNPs in high linkage disequilibrium were associated with a higher risk of clinical fracture that was attenuated by cinacalcet treatment in the EA sample (P<0.04). CONCLUSIONS: These modest associations, if validated, may provide explanations for differences in CKD-mineral bone disorder observed in EA and AfAn populations, and for differential biochemical responses to calcimimetics.
Authors: Sharon M Moe; Glenn M Chertow; Jack W Coburn; L Darryl Quarles; William G Goodman; Geoffrey A Block; Tilman B Drüeke; John Cunningham; Donald J Sherrard; Laura C McCary; Kurt A Olson; Stewart A Turner; Kevin J Martin Journal: Kidney Int Date: 2005-02 Impact factor: 10.612
Authors: B Peter Sawaya; Rezkalla Butros; Shehzab Naqvi; Zhaopo Geng; Hanna Mawad; Robert Friedler; Paolo Fanti; Marie-Claude Monier-Faugere; Hartmut H Malluche Journal: Kidney Int Date: 2003-08 Impact factor: 10.612
Authors: Tae-Hwi Schwantes-An; Matteo Vatta; Marco Abreu; Leah Wetherill; Howard J Edenberg; Tatiana M Foroud; Glenn M Chertow; Sharon M Moe Journal: Cardiorenal Med Date: 2021-08-10 Impact factor: 4.360
Authors: Marciana L Laster; Bryce Rowan; Hua-Chang Chen; Tae-Hwi Schwantes-An; Xin Sheng; Peter A Friedman; T Alp Ikizler; Janet S Sinshiemer; Joachim H Ix; Katalin Susztak; Ian H de Boer; Bryan Kestenbaum; Adriana Hung; Sharon M Moe; Farzana Perwad; Cassianne Robinson-Cohen Journal: J Clin Endocrinol Metab Date: 2022-08-18 Impact factor: 6.134
Authors: Tae-Hwi Schwantes-An; Sai Liu; Margaret Stedman; Brian S Decker; Leah Wetherill; Howard J Edenberg; Matteo Vatta; Tatiana M Foroud; Glenn M Chertow; Sharon M Moe Journal: Am J Nephrol Date: 2019-01-22 Impact factor: 3.754